Risk Factors for Progression to Alzheimer's Disease in African Americans in a Large National Cohort
Kim, Y.; Savitz, S. I.; Lee, J.; Schulz, P. E.; Chen, L.; Jiang, X.
Show abstract
ObjectivesTo investigate risk factors for progression to Alzheimers disease and related dementias (ADRD) in African Americans and non-Hispanic Caucasians in a large US cohort. DesignA matched case-control design using electronic health records (EHRs) from 2000 - 2017. SettingCerner EHRs database covering more than 600 Cerner client hospitals. Participants: 79,120 patients aged 65 and older (#ADRD=39,560, #non ADRD older adults=39,560) from an initial cohort of 49,826,000 patients. MeasurementsWe converted ICD9 or ICD10 diagnosis codes into PheWas codes to increase clinical relevance. Then we detected ADRD as having both ADRD diagnosis codes and medications. We considered PheWas codes for Alzheimers disease, dementia with cerebral degenerations, senile dementia, and vascular dementia. We considered ADRD medications including acetylcholine and memantine. ResultsUsing two-step propensity score matching, we built an African American cohort of 4,429 and a 4,570-person matched Caucasian cohort that was similar in terms of onset age, observation length, sex, and known ADRD risks (diabetes, vascular disease, heart disease, head injury, and obesity). Older African Americans had a statistically significant progression from cerebrovascular risk (transient ischemic attack) to ADRD incidence (treatment effect coefficient = 0.0978, p-value <0.000) whereas the matched Caucasians did not (treatment effect coefficient = 0.403, p-value = 0.196). ConclusionOur extensive causal analysis using a nationwide EHR discovered disease progression pathways to ADRD. The carefully matched cohorts from different racial groups showed different progression, which partly explains the racial disparities in ADRD incidence. IMPACT STATEMENTWe certify that this work is confirmatory of recent novel clinical research. We confirmed that cerebrovascular disease increases the risk of ADRD incidence more in older African Americans than in non-Hispanic Caucasians when diabetes is controlled.1,2 This research adds large-scale and nationwide epidemiological evidence on racial disparities due to cerebrovascular risk.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Blood Biomarkers for Diagnosis & Differential Diagnosis of Alzheimers Disease in Real-World Clinical Populations: A Systematic Review 94%
- Cardiometabolic Indicators of Cognitive Impairment in The Cameron County Hispanic Cohort 94%
- Race/Ethnic Disparities in Mild Cognitive Impairment and Dementia: The Northern Manhattan Study 94%
Similar papers in this journal
- Subjective cognition trajectories, Alzheimer biomarkers, and incident mild cognitive impairment 94%
- Use of Lecanemab and Donanemab in the Canadian Healthcare System: Evidence, Challenges, and Areas for Future Research 93%
- Potentially Modifiable Dementia Risk Factors in Canada: An Analysis of Canadian Longitudinal Study on Aging with a Multi-Country Comparison 93%
Similar papers in this journal
- Continuum of Core 1 Biomarkers in Preclinical Alzheimers Disease 94%
- Interactive Effects of Telomere Length and Genetic Variants on Alzheimer Disease Risk Across Multiple Ancestral Populations 94%
- Development and validation of a harmonized memory score for multicenter Alzheimer's disease and related dementia research 94%
Similar papers in this journal
- Risk models based on non-cognitive measures may identify presymptomatic Alzheimer’s disease 95%
- Alzheimer's disease susceptibility gene apolipoprotein e (APOE) and blood biomarkers in UK Biobank (N=395,769). 94%
- Examining a Preclinical Alzheimer’s Cognitive Composite for Telehealth Administration, the tPACC, for Reliability between In-Person and Remote Cognitive Testing with Neuroimaging Biomarkers 94%